See more : Hertz Lithium Inc. (HZLIF) Income Statement Analysis – Financial Results
Complete financial analysis of INmune Bio, Inc. (INMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INmune Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SSR Mining Inc. (SSRM) Income Statement Analysis – Financial Results
- Strauss Group Ltd. (SGLJF) Income Statement Analysis – Financial Results
- Stratasys Ltd. (SSYS) Income Statement Analysis – Financial Results
- Manor Estates and Industries Limited (KARANWO.BO) Income Statement Analysis – Financial Results
- RAVENO Capital AG (TUF.DE) Income Statement Analysis – Financial Results
INmune Bio, Inc. (INMB)
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.27M | 17.07M | 20.54M | 5.92M | 3.28M | 1.11M | 435.36K | 101.50K | 0.00 |
| General & Administrative | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 195.47K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -146.60K |
| SG&A | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 48.87K |
| Other Expenses | 0.00 | -1.35M | -1.19M | 128.52K | 0.00 | 0.00 | -6.00 | 0.00 | 0.00 |
| Operating Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Cost & Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 77.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.74M | 25.95M | 29.15M | 12.23M | 9.30M | 12.44M | 981.48K | 227.49K | 195.47K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 149.99K | -50.00K | 146.60K |
| EBITDA Ratio | 0.00% | -6,938.77% | -16,106.63% | -112,016.09% | -13.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.74M | -25.95M | -29.15M | -12.23M | -7.76M | -12.44M | -981.48K | -227.49K | -48.87K |
| Operating Income Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -9.98% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -267.00K | -1.35M | -1.19M | 129.00K | 77.69K | 0.00 | 149.99K | -50.00K | 0.00 |
| Income Before Tax | -30.01M | -27.30M | -30.34M | -12.10M | -7.68M | -12.44M | -831.49K | -277.49K | -48.87K |
| Income Before Tax Ratio | -19,360.00% | -7,299.20% | -16,762.43% | -110,838.76% | -9.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.35M | -29.15M | -12.23M | 1.46M | -161.14K | -1.13M | -177.49K | 0.00 |
| Net Income | -30.01M | -28.65M | -30.34M | -12.10M | -9.14M | -12.44M | -831.49K | -277.49K | -48.87K |
| Net Income Ratio | -19,360.00% | -7,659.63% | -16,762.43% | -110,838.76% | -11.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| EPS Diluted | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
| Weighted Avg Shares Out (Dil) | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
INmune Bio, High Risk, Higher Reward.
The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities. XPro looks especially promising in mild cognitive decline and early Alzheimer's and could be a real blockbuster drug.
INmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnum - Head of Neuroscience Dr. Mark...
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
Management to host conference call and webcast at 4:30 pm E T on that day
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
INmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Co-Founder and Chief Executive Officer Mark Lowdell – Co-Founder and Chief...
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
INmune Bio: Possibly The Once In A Lifetime Dip
INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB's share price just dropped at an all-time low due to a US-related clinical hold for XPro.
INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade
Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New...
INmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Executive Officer CJ Barnum – Head of Neuroscience...
Source: https://incomestatements.info
Category: Stock Reports